These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21212803)

  • 1. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.
    Cacchiarelli D; Incitti T; Martone J; Cesana M; Cazzella V; Santini T; Sthandier O; Bozzoni I
    EMBO Rep; 2011 Feb; 12(2):136-41. PubMed ID: 21212803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.
    Fiorillo AA; Heier CR; Novak JS; Tully CB; Brown KJ; Uaesoontrachoon K; Vila MC; Ngheim PP; Bello L; Kornegay JN; Angelini C; Partridge TA; Nagaraju K; Hoffman EP
    Cell Rep; 2015 Sep; 12(10):1678-90. PubMed ID: 26321630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
    Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
    Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.
    Cazzella V; Martone J; Pinnarò C; Santini T; Twayana SS; Sthandier O; D'Amico A; Ricotti V; Bertini E; Muntoni F; Bozzoni I
    Mol Ther; 2012 Nov; 20(11):2134-42. PubMed ID: 22968481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DMD transcript imbalance determines dystrophin levels.
    Spitali P; van den Bergen JC; Verhaart IE; Wokke B; Janson AA; van den Eijnde R; den Dunnen JT; Laros JF; Verschuuren JJ; 't Hoen PA; Aartsma-Rus A
    FASEB J; 2013 Dec; 27(12):4909-16. PubMed ID: 23975932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy.
    Endesfelder S; Bucher S; Kliche A; Reszka R; Speer A
    J Mol Med (Berl); 2003 Jun; 81(6):355-62. PubMed ID: 12732930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PITX2 Enhances the Regenerative Potential of Dystrophic Skeletal Muscle Stem Cells.
    Vallejo D; Hernández-Torres F; Lozano-Velasco E; Rodriguez-Outeiriño L; Carvajal A; Creus C; Franco D; Aránega AE
    Stem Cell Reports; 2018 Apr; 10(4):1398-1411. PubMed ID: 29641992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelination is delayed during postnatal brain development in the mdx mouse model of Duchenne muscular dystrophy.
    Aranmolate A; Tse N; Colognato H
    BMC Neurosci; 2017 Aug; 18(1):63. PubMed ID: 28806929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.